ISB News

ISB’s Robert Moritz Lab Receives NIGMS Grant for Trans Proteomic Pipeline

The National Institute Of General Medical Sciences of the NIH has awarded Principal Investigator(s): Eric Deutsch, PhD, and Robert L. Moritz, PhD, a continuing R01 grant GM087221 for the ongoing development of the Trans-Proteomic Pipeline. The award titled “Development of Trans Proteomic Pipeline, an Analysis Suite for Mass Spectrometry” will continue the work of the ISB flagship proteomics analysis suite of open-source programs that has been downloaded thousands of times by researchers worldwide. The TPP team will continue on its effort of building new tools and teaching researchers (see previous post about ISB’s TPP course) from across the globe how to access new statistical validation and cloud-enabled components of the TPP. The grant will provide ISB with direct costs of $287,000 each year for the next 4 years for Deutsch, Luis Mendoza, David Shteynberg and Zhi Sun of the Moritz group to continue this work.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.